Adrenocortical steroid hormones play a major role in the regulation of both action and metabolism of catecholamines. However, there is limited information on the effect of prolonged increase in plasma steroid hormone concentration on the sympathetic nervous system, which is the main source of norepinephrine. Using a double-blind, placebo-controlled cross-over design, we examined 20 male healthy volunteers after acute administration of 40 mg hydrocortisone or matching placebo as well as after a 1-week treatment with this steroid (daily dose, 40 mg) or placebo. Sympathetic nervous system activity was assessed by determination of overnight urinary norepinephrine and epinephrine secretion and by analysis of short-time heart rate variability (HRV) measures in the frequency domain. The low-frequency (LF) component of the HRV spectrum was considered to reflect both sympathetic and parasympathetic modulation and the high-frequency (HF) band vagal activity. HRV testing included the response to a mild cardiovascular challenge, orthostasis. After 1 subject had been excluded because of incompliance with the study medication, the data of 19 subjects were used for further analyses. Prolonged hydrocortisone treatment was associated with a significant shift of relative power from the LF to the HF band in the upright position, resulting in a significant decrease in the LF/HF ratio (placebo 6.77 ± 3.35 and hydrocortisone 4.72 ± 3.27; p < 0.05). No differences between groups were observed after acute steroid administration or after prolonged treatment in the supine position. Neither acute nor chronic hydrocortisone treatment resulted in significant changes in the overnight urinary catecholamine secretion. Our data suggest that prolonged but not acute hydrocortisone administration shifts the autonomic response to an orthostatic challenge towards parasympathetic activity.

Keywords:
Clinical neuroendocrinology, Adrenal steroids, Autonomous nervous system, Catecholamines, Orthostatic challenge, Stress
1.
Nonell A, Kerk S, Lederbogen F, Kopf D, Hamann B, Lewicka S, Deuschle M: No major effect of orciprenalin and propranolol upon ACTH-induced cortisol secretion. Exp Clin Endocrinol Diabetes 2004;112:59–61.
2.
Ehrhart-Bornstein M, Hinson JP, Bornstein SR, Scherbaum WA, Vinson GP: Intraadrenal interactions in the regulation of adrenocortical steroidogenesis. Endocr Rev 1998;19:101–143.
3.
Ceccatelli S, Dagerlind A, Schalling M, Wikstrom AC, Okret S, Gustavsson JA, Goldstein M, Hokfelt T: The glucocorticoid receptor in the adrenal gland is localized in the cytoplasm of adrenal cells. Acta Physiol Scand 1989;137:559–560.
4.
Ross ME, Evinger MJ, Hyman SE, Caroll JM, Mucke L, Comb M, Reis DJ, Joh TH, Goodman HM: Identification of a functional glucocorticoid response element in the phenylethanolamine N-methyltransferase promoter using fusion genes introduced into chromaffin cells in primary cultures. J Neurosci 1990;10:520–530.
5.
Wurtman RJ, Axelrod J: Control of enzymatic synthesis of adrenaline in the adrenal medulla by adrenal cortical steroids. J Biol Chem 1966;241:2301–2305.
6.
Cameron OG, Starkman MN, Schteingart DE: The effect of elevated systemic cortisol levels on plasma catecholamines in Cushing’s syndrome patients with and without depressed mood. J Psychiatr Res 1995;29:347–360.
7.
Maas JW: Adrenocortical steroid hormones, electrolytes, and the disposition of the catecholamines with particular reference to depressive states. J Psychiatr Res 1972;9:227–241.
8.
Kalsner S: Mechanism of hydrocortisone potentiation of responses to epinephrine and norepinephrine in rabbit aorta. Circ Res 1969;26:383–395.
9.
Dodt C, Wallin G, Fehm HL, Elam M: The stress hormone adrenocorticotropin enhances sympathetic outflow to the muscle vascular bed in humans. J Hypertens 1998;16:195–201.
10.
Macefield VG, Williamson PM, Wilson LR, Kelly JJ, Gandevia SC, Whitworth JA: Muscle sympathetic vasoconstrictor activity in hydrocortisone-induced hypertension in humans. Blood Press 1998;7:215–222.
11.
Kvetnansky R, Fukuhara K, Pacak K, Cizza G, Goldstein DS, Kopin JJ: Endogenous glucocorticoids restrain catecholamine synthesis and release at rest and during immobilization stress in rats. Endocrinology 1993;133:1411–1409.
12.
Pacak K, Kvetnansky R, Palkovits M, Fukuhara K, Yadid G, Kopin JJ, Goldstein DS: Adrenalectomy augments in vivo release of norepinephrine in the paraventricular nucleus during immobilization stress. Endocrinology 1993;133:1404–1410.
13.
McCance AJ, Thompson PA, Forfar JC: Increased cardiac sympathetic nervous activity in patients with unstable coronary heart disease. Eur Heart J 1993;14:751–757.
14.
Deuschle M, Schweiger U, Weber B, Gotthardt U, Körner A, Schmider J, Standhardt H, Lammers C, Heuser I: Diurnal activity and pulsatility of the hypothalamus-pituitary-adrenal system in male depressed patients and healthy controls. J Clin Endocrinol Metab 1997;82:234–238.
15.
Chrousos GP, Gold PW: The concepts of stress and stress system disorders. JAMA 1992;267:1244–1252.
16.
Chrousos GP: The role of stress and the hypothalamic-pituitary-adrenal axis in the pathogenesis of the metabolic syndrome: Neuroendocrine and target tissue-related causes. Int J Obes 2000;24:50–55.
17.
Glassman AH, Shapiro PA: Depression and the course of coronary artery disease. Am J Psychiatry 1998;155:4–11.
18.
Berntson GG, Bigger T, Eckberg DL, Grossman P, Kaufmann PG, Malik M, Nagaraja HN, Porges SW, Saul JP, Stone PH, Van der Molen JW: Heart rate variability: Origins, methods, and interpretive caveats. Psychophysiology 1997;34:623–648.
19.
La Rovere MT, Bigger JT, Marcus FI, Mortara A, Schwartz PJ: Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) Investigators. Lancet 1998;351:478–484.
20.
Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology: Heart rate variability. Standards of measurement, physiological interpretation, and clinical use. Circulation 1996;93:1043–1065.
21.
Scott LV, Dinan TG: Urinary free cortisol excretion in chronic fatigue syndrome, major depression and in healthy volunteers. J Affect Disord 1998;47:49–54.
22.
Schommer NC, Hellhammer DH, Kirschbaum C: Dissociation between reactivity of the hypothalamus-pituitary-adrenal axis and the sympathetic-adrenal-medullary system to repeated psychosocial stress. Psychosom Med 2003;65:450–460.
23.
Malliani A, Pagani M, Lombardi F: Physiology and clinical implications of variability of cardiovascular parameters with focus on heart rate and blood pressure. Am J Cardiol 1994;73:3–9.
24.
Malik M, Camm AJ: Components of heart rate variability – What they really mean and what we really measure. Am J Cardiol 1993;72:821–822.
25.
Kuroiwa Y, Wada T, Toghi H: Measurement of blood pressure and heart rate variation while resting supine and standing for the evaluation of autonomic dysfunction. J Neurol 1987;235:65–68.
26.
Pomeranz B, Macaulay RJ, Caudill MA, Kutz I, Adam D, Gordon D, Kilborn KM, Barger A, Shannon DC, Cohen RJ, Benson H: Assessment of autonomic function in humans by heart rate spectral analysis. Am J Physiol 1985;248:151–153.
27.
Rimoldi O, Pierini S, Ferrari A, Cerutti S, Pagani M, Malliani A: Analysis of short-term oscillations of RR and arterial pressure in conscious dogs. Am J Physiol 1990;258:967–976.
28.
Watkins LL, Grossman P: Association of depressive symptoms with reduced baroreflex cardiac control in coronary heart disease. Am Heart J 1999;137:453–457.
29.
McFarlane A, Kamath MV, Fallen EL, Malcolm V, Cherian F, Norman G: Effect of sertraline on the recovery rate of cardiac autonomic function in depressed patients after acute myocardial infarction. Am Heart J 2001;142:617–623.
30.
Lombardi F, Sandrone G, Pernpruner S, Sala R, Garimoldi M, Cerutti S, Baselli G, Pagani M, Malliani A: Heart rate variability as an index of sympathovagal interaction after acute myocardial infarction. Am J Cardiol 1987;60:1239–1245.
31.
Odemuyiwa O, Malik M, Farrell T, Bashir Y, Poloniecki J, Camm J: Comparison of the predictive characteristics of heart rate variability index and left ventricular ejection fraction for all-cause mortality, arrhythmic events and sudden death after acute myocardial infarction. Am J Cardiol 1991;68:434–439.
32.
Bigger JT, Fleiss JL, Rolnitzky LM, Steinmann RC: The ability of several short-term measures of heart rate variability to predict mortality after myocardial infarction. Circulation 1993;88:927–934.
33.
Lenders JW, Golczynska A, Goldstein DS: Glucocorticoids, sympathetic activity, and presynaptic α-adrenoceptor function in humans. J Clin Endocrinol Metab 1995;80:1804–1808.
34.
Arlt J, Jahn H, Kellner M, Strohle A, Yassouridis A, Wiedemann K: Modulation of sympathetic activity by corticotropin-releasing hormone and atrial natriuretic peptide. Neuropeptides 2003;37:362–368.
35.
Vozarova B, Weyer C, Snitker S, Gautier JF, Cizza G, Chrousos G, Ravussin E, Tatatanni PA: Effect of cortisol on muscle sympathetic nerve activity in Pima Indians and Caucasians. J Clin Endocrinol Metab 2003;88:3218–3226.
36.
Hughes JW, Stoney CM: Depressed mood is related to high-frequency heart rate variability during stressors. Psychosom Med 2000;62:796–803.
© 2005 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.